CVS Health Corporation $CVS Stock Sold by Community Trust & Investment Co.

Community Trust & Investment Co. lowered its stake in shares of CVS Health Corporation (NYSE:CVS) by 5.2% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 232,385 shares of the pharmacy operator’s stock after selling 12,798 shares during the period. Community Trust & Investment Co.’s holdings in CVS Health were worth $19,913,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently modified their holdings of the company. Community Financial Services Group LLC purchased a new position in CVS Health in the 3rd quarter worth $39,000. Triasima Portfolio Management inc. grew its position in CVS Health by 119.8% during the 3rd quarter. Triasima Portfolio Management inc. now owns 71,917 shares of the pharmacy operator’s stock worth $6,163,000 after purchasing an additional 39,202 shares during the period. Assenagon Asset Management S.A. raised its stake in shares of CVS Health by 148.8% during the 3rd quarter. Assenagon Asset Management S.A. now owns 4,419,866 shares of the pharmacy operator’s stock valued at $378,738,000 after buying an additional 2,643,571 shares during the last quarter. Ninety One UK Ltd purchased a new position in CVS Health during the third quarter valued at approximately $222,000. Finally, State of Alaska Department of Revenue lifted its holdings in CVS Health by 24.0% in the third quarter. State of Alaska Department of Revenue now owns 192,696 shares of the pharmacy operator’s stock valued at $16,512,000 after acquiring an additional 37,259 shares during the period. Institutional investors own 80.66% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the stock. Bank of America increased their target price on shares of CVS Health from $100.00 to $110.00 and gave the stock a “buy” rating in a research note on Monday, June 22nd. Leerink Partners decreased their target price on CVS Health from $119.00 to $112.00 and set an “outperform” rating on the stock in a research report on Monday. HSBC reiterated a “hold” rating and issued a $103.00 price objective on shares of CVS Health in a report on Monday, July 6th. Barclays lifted their price objective on CVS Health from $106.00 to $108.00 and gave the stock an “overweight” rating in a research report on Thursday, August 6th. Finally, Robert W. Baird set a $107.00 price objective on shares of CVS Health in a report on Thursday, August 6th. Twenty research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, CVS Health has an average rating of “Moderate Buy” and an average price target of $107.80.

CVS Health Price Performance

Shares of NYSE:CVS opened at $92.45 on Friday. CVS Health Corporation has a 12 month low of $69.51 and a 12 month high of $110.68. The company has a debt-to-equity ratio of 0.74, a current ratio of 0.87 and a quick ratio of 0.66. The firm has a market capitalization of $118.25 billion, a P/E ratio of 24.46, a P/E/G ratio of 0.84 and a beta of 0.60. The company’s fifty day moving average price is $91.80 and its 200 day moving average price is $93.03.

CVS Health (NYSE:CVS) last issued its quarterly earnings results on Wednesday, August 5th. The pharmacy operator reported $2.58 earnings per share for the quarter, topping analysts’ consensus estimates of $1.87 by $0.71. CVS Health had a net margin of 1.18% and a return on equity of 13.12%. The firm had revenue of $106.10 billion during the quarter, compared to analysts’ expectations of $100.03 billion. During the same quarter in the prior year, the business earned $1.81 EPS. CVS Health’s quarterly revenue was up 7.3% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. As a group, sell-side analysts predict that CVS Health Corporation will post 8.02 earnings per share for the current fiscal year.

CVS Health Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, November 2nd. Stockholders of record on Thursday, October 22nd will be paid a dividend of $0.6650 per share. This represents a $2.66 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date of this dividend is Thursday, October 22nd. CVS Health’s dividend payout ratio (DPR) is 70.37%.

Key Headlines Impacting CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Improving fundamentals and valuation support the stock. CVS has recently exceeded earnings and revenue expectations, while analysts cited stronger returns, rising earnings estimates and a lower valuation than Alignment Healthcare. Its Aetna turnaround is also viewed as a potential catalyst. CVS vs. ALHC: Which Medicare Advantage Stock Is the Better Pick Now?
• Positive Sentiment: Expanded care access and quality credentials reinforce CVS’s healthcare-services strategy. CVS opened its first pharmacy-focused location in the Boston area to improve access to medications, immunizations and other services. Separately, MinuteClinic received its seventh consecutive Joint Commission accreditation, with primary care available at more than 65% of its locations. CVS Pharmacy Celebrates Opening of First Pharmacy-Focused Location in Boston Area
• Neutral Sentiment: New women’s-health collaboration could support longer-term engagement. CVS is partnering with The Midlife Collective on a research study and documentary focused on women’s midlife health. The initiative may strengthen brand awareness and consumer relationships, but it is unlikely to have a near-term financial impact. CVS Health Collaborates With The Midlife Collective
• Positive Sentiment: Home-based heart monitoring expands value-added services. Signify Health, part of CVS, offers continuous heart-rhythm monitoring for eligible health-plan members, potentially enabling earlier detection of serious conditions and supporting preventive-care economics. CVS Health: Early Detection Matters
• Negative Sentiment: $315 million opioid settlement creates legal, financial and reputational pressure. CVS agreed to settle Justice Department allegations involving unlawful opioid dispensing and false claims. The company admitted no wrongdoing but will implement tighter controlled-substance oversight, adding costs and highlighting compliance risks. CVS Agrees to Pay $315M

About CVS Health

CVS Health Corp. is an integrated health care company that provides pharmacy, insurance and health services primarily in the United States. Its operations are designed to connect consumers, health plans, health care providers and pharmacy services across multiple points of care.

The company’s major businesses include CVS Pharmacy retail locations, prescription fulfillment and consumer health products; CVS Caremark, a pharmacy benefit management business; and Aetna, which offers health insurance products and related services for employers, individuals, government programs and other organizations.